Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cyclo Therapeutics Inc (CYTH)

Cyclo Therapeutics Inc (CYTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cyclo Therapeutics Inc 6714 NW 16TH STREET SUITE B GAINESVILLE FL 32653 USA

www.cyclotherapeutics.com P: 386-418-8060 F: 321-244-8351

Description:

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.

Key Statistics

Overview:

Market Capitalization, $K 41,638
Enterprise Value, $K 32,388
Shares Outstanding, K 28,716
Annual Sales, $ 1,080 K
Annual Net Income, $ -20,060 K
Last Quarter Sales, $ 310 K
Last Quarter Net Income, $ -5,640 K
EBIT, $ -20,030 K
EBITDA, $ -20,010 K
60-Month Beta -0.18
% of Insider Shareholders 29.78%
% of Institutional Shareholders 68.55%
Float, K 20,164
% Float 70.22%
Short Volume Ratio 0.54

Growth:

1-Year Return 20.49%
3-Year Return -79.29%
5-Year Return 0.00%
5-Year Revenue Growth 6.93%
5-Year Earnings Growth 75.40%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.23 on 03/18/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -1.31
EPS Growth vs. Prev Qtr 20.69%
EPS Growth vs. Prev Year 61.02%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CYTH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -4,506.97%
Return-on-Assets % -290.82%
Profit Margin % -1,857.41%
Debt/Equity 0.00
Price/Sales 40.03
Price/Cash Flow N/A
Price/Book 7.22
Book Value/Share 0.21
Interest Coverage -1.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar